$0.00
+0.00 (+50.00%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LIPO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluating LP-10 in Subjects With OLPNCT06233591To evaluate the safety of LP-10 in patients with oral lichen PlanusNon-randomized · Open-label · Treatment | Phase 2 | Unknown status | Drug: LP-10 (Liposomal Tacrolimus) | Oral Lichen Planus | 24 | 2025-06-01 | 2025-05-15 |
| The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic CystitisNCT03129126Patient Reported Mean episodes of visible bloodNon-randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: LP-10 | Hemorrhagic Cystitis | 13 | 2023-08-21actual | 2023-12-11 |
| Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder SyndromeNCT01393223Safety of Intravesical LP08: number/severity of adverse eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: LP-08 80mg, Normal saline, LP-08 20mg | Interstitial Cystitis | 21 | 2018-06-14actual | 2018-11-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19